Insulin detemir for diabetes mellitus
Canadian Coordinating Office for Health Technology Assessment
Record ID 32004000647
English, French
Authors' objectives:
To summarize the available information on the use of insulin detemir (Trade Name: Levemir, manufactured by Novo Nordisk) for the management of type 1 (insulin dependent) diabetes mellitus (DM) and type 2 (non-insulin dependent) DM.
Authors' recommendations:
Insulin detemir is a new long-acting insulin analogue for the treatment of type 1 and type 2 DM. It does not improve HbA1c control or reduce overall hypoglycemic events in most trials that compare it to NPH insulin. It may be advantageous for those who experience nocturnal hypoglycemia or weight gain with NPH insulin. The one trial that compared this insulin to insulin glargine (a new long-acting insulin that has been approved by Health Canada but is not yet marketed) did not measure or report on clinical outcomes. It is impossible to make a clinical comparison between these two long-acting products. More published research is needed to clarify insulin detemir's place in therapy.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Insulin
- Diabetes Mellitus
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.